News for Olema Pharmaceuticals, Inc. (OLMA)

SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (”œOlema” or ”œOlema Oncology”, OLMA), a clinical-stage biopharmaceutical

**media[545029]**

SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (”œOlema” or ”œOlema Oncology”, OLMA), a clinical-stage biopharmaceutical

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.

Significant Stock Acquisition by Paradigm Biocapital Advisors LP (Trades, Portfolio) On December 31, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) e

**media[532245]**

Insider Trading Roundup: Monday's Top Buys and Sells in US Stocks

**media[505234]**

**media[504083]**

SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (”œOlema” or ”œOlema Oncology”, OLMA), a clinical-stage biopharmaceutical

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Olema Pharmaceuticals stock hits 52-week low at $7.67

**media[487004]**

Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (”œOlema” or â

PR NewswireROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a gl

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Shares of Intuitive Surgical, Inc. ISRG rose sharply in today's pre-market trading as the company posted better-than-expected third-quarter financial results. ...

Loading... Loading... Shares of Science Applications International Corporation SAIC declined 11% to $119.91 following first-quarter results. SAIC reported a 9...